An 11-Gene Signature Based on Treatment Responsiveness Predicts Radiation Therapy Survival Benefit Among Breast Cancer Patients

• DOI: 10.3389/fonc.2021.816053
• Publication Date: 2022-01-06T05:16:40Z
• Authors: Junjie Shen; Derui Yan; Lu Bai; Ruirui Geng; Xulun Zhao; Huijun Li; Yongfei Dong; Jianping Cao; Zaixiang Tang; Song-bai Liu
• Keywords: Gene signature

We developed a strategy of building prognosis gene signature based on clinical treatment responsiveness to predict radiotherapy survival benefit in breast cancer patients.Analyzed data came from the public database. PFS was used as an indicator responsiveness. WGCNA identify most relevant modules response. Based module genes, Cox regression model build distinguish group radiotherapy. An external validation also performed.In dataset, MEbrown with 534 genes identified by WGCNA, which correlated response patients. A number 11 hub were selected signature. Patients that divided into radio-sensitivity and radio-resistant risk score had varied benefit. In 3-, 5-, 10-year AUC 0.814 (CI95%: 0.742-0.905), 0.781 0.682-0.880), 0.762 0.626-0.897), respectively. 3- 5-year 0.706 0.523-0.889) 0.743 0.595-0.891). The higher predictive power than factors alone more efficiency. Functional enrichment analysis revealed mainly enriched immune-related processes. Further immune estimated showed difference distribution micro-environment between group.The 11-gene may reflect differences tumor underlie differential radiation therapy could guide clinical-decision making related